GILEAD SCIENCES INC (1GILD.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1GILD - US3755581036 - Common Stock
1GILD.MI Key Statistics, Chart & Performance
The current stock price of 1GILD.MI is 105.88 EUR. In the past month the price decreased by -0.56%.
1GILD.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 72.89 | 48.25B | ||
| ARGX.BR | ARGENX SE | 71.83 | 47.54B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.44B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.31B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.78B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.77B | ||
| 5CV.DE | CUREVAC NV | 5.45 | 1.07B | ||
| NANO.PA | NANOBIOTIX | N/A | 866.91M | ||
| PHIL.MI | PHILOGEN SPA | 20.04 | 668.13M | ||
| IVA.PA | INVENTIVA SA | N/A | 704.86M | ||
| 6IV.DE | INVENTIVA SA | N/A | 651.37M |
Related stock screener links
About 1GILD.MI
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 17600
Phone: 16505743000
GILEAD SCIENCES INC / 1GILD.MI FAQ
What does GILEAD SCIENCES INC do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.
What is the stock price of GILEAD SCIENCES INC today?
The current stock price of 1GILD.MI is 105.88 EUR. The price increased by 7.86% in the last trading session.
Does 1GILD stock pay dividends?
GILEAD SCIENCES INC (1GILD.MI) has a dividend yield of 2.67%. The yearly dividend amount is currently 2.72.
How is the ChartMill rating for GILEAD SCIENCES INC?
1GILD.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is GILEAD SCIENCES INC (1GILD.MI) expected to grow?
The Revenue of GILEAD SCIENCES INC (1GILD.MI) is expected to grow by 1.79% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for GILEAD SCIENCES INC?
GILEAD SCIENCES INC (1GILD.MI) currently has 17600 employees.
When does GILEAD SCIENCES INC (1GILD.MI) report earnings?
GILEAD SCIENCES INC (1GILD.MI) will report earnings on 2026-02-09, after the market close.
1GILD.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 1GILD.MI.
1GILD.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1GILD.MI. While 1GILD.MI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
1GILD.MI Financial Highlights
Over the last trailing twelve months 1GILD.MI reported a non-GAAP Earnings per Share(EPS) of 7.09. The EPS increased by 84.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.88% | ||
| ROA | 13.86% | ||
| ROE | 37.8% | ||
| Debt/Equity | 0 |
1GILD.MI Forecast & Estimates
36 analysts have analysed 1GILD.MI and the average price target is 112.24 EUR. This implies a price increase of 6.01% is expected in the next year compared to the current price of 105.88.
For the next year, analysts expect an EPS growth of 77.74% and a revenue growth 1.79% for 1GILD.MI